Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Estrogen Receptor Positive

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Estrogen Receptor Positive cohort.

Asset / SponsorPhaseRating
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Zoladex
Memorial Sloan Kettering Cancer Center
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 2BB
(+)-VINCRISTINE
Queen Mary University of London
Phase 3BB
Cediranib
Jonsson Comprehensive Cancer Center
Phase 2BB

View all 42 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →